Aprea Therapeutics, Inc. (APRE:NASDAQ) Investor Relations Material

Overview

Doylestown, Pennsylvania-based Aprea Therapeutics, Inc. is making strides in its mission to create and distribute cancer therapeutics that utilize synthetic lethality. The biopharmaceutical company is concentrating its efforts on attacking a critical DNA damage response pathway and central targets in cancer progression. ATRN-119, the firm's premier program, is a small molecule ATR inhibitor that is currently undergoing clinical testing for the treatment of solid tumors.

Annual Reports

Frequently Asked Questions

What is Aprea Therapeutics, Inc.'s ticker?

Aprea Therapeutics, Inc.'s ticker is APRE

What exchange is Aprea Therapeutics, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Aprea Therapeutics, Inc.'s headquarters?

They are based in Boston, Massachusetts

How many employees does Aprea Therapeutics, Inc. have?

There are 11-50 employees working at Aprea Therapeutics, Inc.

What is Aprea Therapeutics, Inc.'s website?

It is https://www.aprea.com/

What type of sector is Aprea Therapeutics, Inc.?

Aprea Therapeutics, Inc. is in the Healthcare sector

What type of industry is Aprea Therapeutics, Inc.?

Aprea Therapeutics, Inc. is in the Biotechnology industry

Who are Aprea Therapeutics, Inc.'s peers and competitors?

The following five companies are Aprea Therapeutics, Inc.'s industry peers:

- Anixa Biosciences

- Precigen

- KalVista Pharmaceuticals, Inc.

- Salarius Pharmaceuticals

- Oncternal Therapeutics, Inc.